Results 171 to 180 of about 22,506 (225)
Lancet, The, 2017 Background: Fibrinolytic therapy offers an alternative to mechanical reperfusion for ST-segment elevation myocardial infarction (STEMI) in settings where health-care resources are scarce.
Peerawat Jinatongthai +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Progress in Cardiovascular Diseases, 1979
W ITHOUT question, degenerative vascular disease remains the major cause of death and morbidity in the Western world. In the United Kingdom, cardiovascular disease is responsible for about 50% of all deaths in men aged 45-54 yr, and this must be compared with only 25% of deaths in this age group resulting from cancers.’ Although little direct proof ...
J F, Davidson, I D, Walker
openaire +2 more sources
W ITHOUT question, degenerative vascular disease remains the major cause of death and morbidity in the Western world. In the United Kingdom, cardiovascular disease is responsible for about 50% of all deaths in men aged 45-54 yr, and this must be compared with only 25% of deaths in this age group resulting from cancers.’ Although little direct proof ...
J F, Davidson, I D, Walker
openaire +2 more sources
Development of New Fibrinolytic Agents
Current Pharmaceutical Design, 2006Since the activation of coagulation system and platelets triggers the thrombosis, the agents possessing anticoagulation or anti-platelet function have been used for the antithrombotic procession actions. However, in the physiological condition, the fibrinolytic system serves as antithrombotic, which removes the thrombus from the circulation.
Shigeru, Ueshima, Osamu, Matsuo
openaire +2 more sources
The clinical use of fibrinolytic agents
The American Journal of Surgery, 1977Two fibrinolytic drugs, streptokinase and urokinase, have undergone extensive clinical evaluation in the past fifteen years. Current evidence suggests that these agents may become the drugs of choice in the treatment of certain patients with venous thrombosis and pulmonary embolism.
J M, Porter, S H, Goodnight
openaire +2 more sources
[Enzymatic fibrinolytic agents].
Annales de l'anesthesiologie francaise, 1979Urokinase (UK) and streptokinase (SK) transform plasminogen into plasmin by rupture of a ARG-VAL bond and the liberation of a peptide with a molecular weight of 6000 to 8000. Urokinase is a physiological activator with a direct action. By contrast, streptokinase is an enzyme of bacterial origin and two hypotheses may be advanced to explain its ...
M, Jamet, C, Granthil, G, Levy
openaire +2 more sources
Pharmacology of fibrinolytic agents
Progress in Cardiovascular Diseases, 1979T HE appreciation of the high morbidity and mortality from thromboembolic occlusive vascular disease has given the impetus to a continuing search for drugs that might be of clinical value in its prevention and treatment. Anticoagulant therapy with heparin or the oral anticoagulants is primarily prophylactic, and while these drugs can prevent the ...
openaire +2 more sources
Thrombosis and Haemostasis, 1966
Summary1. Caseinolytic and fibrinolytic systems for assay of plasmin in fibrinolytic agents are described which are based upon the determinations of AE/min during the linear portion of the casein-plasmin and fibrin-plasmin reaction curves respectively. A " caseinolytic-rate " unit and “fibrinolytic-rate " unit of ÄE/min × 103 during the linear portion ...
K M, Moser, M B, Frey
openaire +2 more sources
Summary1. Caseinolytic and fibrinolytic systems for assay of plasmin in fibrinolytic agents are described which are based upon the determinations of AE/min during the linear portion of the casein-plasmin and fibrin-plasmin reaction curves respectively. A " caseinolytic-rate " unit and “fibrinolytic-rate " unit of ÄE/min × 103 during the linear portion ...
K M, Moser, M B, Frey
openaire +2 more sources
Tenecteplase: A promising new fibrinolytic agent
Dimensions of Critical Care Nursing, 2001Acute coronary syndrome can mean anything from unstable angina to acute myocardial infarction (MI) with ST-segment elevation. Tenecteplase, a new fibrinolytic agent used to treat ST-segment elevation acute MI, has some advantages over other fibrinolytic agents. This article describes tenecteplase's actions, indications, contraindications, and use.
M J, De Jong, W, Sabadie-Garretson
openaire +2 more sources
Fibrinolytic Agents: Mechanisms of Activity and Pharmacology
Thrombosis and Haemostasis, 1995Fibrinolytic (thrombolytic) agents activate the fibrinolytic system by conversion of the inactive proenzyme, plasminogen into the active enzyme plasmin, that degrades fibrin. Agents available for clinical use are: the physiologic tissue-type plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA)--either in a single chain (scu-PA ...
H R, Lijnen, D, Collen
openaire +2 more sources
ROLE OF FIBRINOLYTIC AGENTS IN THROMBOTIC DISEASES
Journal of the American Medical Association, 1960Critical analysis of existing data demonstrates that fibrinolysin in conjunction with anticoagulant therapy decreases the morbidity in patients with thrombophlebitis. This conclusion was the result of comparison of data from hospital charts of 20 patients in a fibrinolysin-treated series and a control group of 22 patients. The comparison was made after
R V, CHAPPLE, H O, SINGHER
openaire +2 more sources